Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study

被引:4
作者
Imai, Hisao [1 ,2 ]
Kaira, Kyoichi [2 ]
Masubuchi, Ken [1 ]
Minato, Koichi [1 ]
机构
[1] Gunma Prefectural Canc Ctr, Div Resp Med, Otaru, Hokkaido 3738550, Japan
[2] Saitama Med Univ, Int Med Ctr, Ctr Comprehens Canc, Dept Resp Med, Hidaka 3500495, Japan
关键词
acute pericarditis; catheter drainage; intrapericardial carboplatin; lung cancer; malignant pericardial effusion; POOR-PROGNOSIS; BLEOMYCIN; INSTILLATION;
D O I
10.3390/curroncol29010015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has been reported that 5.1-7.0% of acute pericarditis are carcinomatous pericarditis. Malignant pericardial effusion (MPE) can progress to cardiac tamponade, which is a life-threatening condition. The effectiveness and feasibility of intrapericardial instillation of carboplatin (CBDCA; 150 mg/body) have never been evaluated in patients with lung cancer, which is the most common cause of MPE. Therefore, we evaluated the effectiveness and feasibility of intrapericardial administration of CBDCA following catheter drainage in patients with lung cancer-associated MPE. In this retrospective study, 21 patients with symptomatic lung cancer-associated MPE, who were administered intrapericardial CBDCA (150 mg/body) at Gunma Prefectural Cancer Center between January 2005 and March 2018, were included. The patients' characteristics, response to treatment, and toxicity incidence were evaluated. Thirty days after the intrapericardial administration of CBDCA, MPE was controlled in 66.7% of the cases. The median survival period from the day of administration until death or last follow-up was 71 days (range: 10-2435 days). Grade 1-2 pain, nausea, fever, and neutropenia were noted after intrapericardial CBDCA administration. No treatment-related deaths were noted in the current study. Intrapericardial administration of CBDCA (150 mg/body) did not cause serious toxicity, and patients exhibited promising responses to lung cancer-associated MPE. Prospective studies using larger sample sizes are needed to explore the efficacy and safety of this treatment for managing lung cancer-associated MPE.
引用
收藏
页码:163 / 172
页数:10
相关论文
共 50 条
  • [31] AUTOANTIBODIES TO A PANEL OF LUNG CANCER-ASSOCIATED ANTIGENS CAN PROVIDE SIGNIFICANT DISCRIMINATION BETWEEN MALIGNANT AND NON-MALIGNANT LUNG NODULES
    Massion, Pierre
    Peek, Laura J.
    Fredericks, Lynn
    Jewell, William
    Pingleton, William W.
    Robertson, John F. R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S979 - S979
  • [32] Development of Pericardial Effusion in Non-small Cell Lung Cancer Is Associated with the Presence of EGFR/ALK Mutations
    Nardi-Agmon, Inbar
    Zer, Alona
    Peysakhovich, Yuri
    Margalit, Ili
    Kornowski, Ran
    Peled, Nir
    Iakobishvili, Zaza
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2022, 24 (03): : 135 - 139
  • [33] Role of early definitive management for newly diagnosed malignant pleural effusion related to lung cancer
    Chiang, Ka-Yan
    Ho, James Chung-Man
    Chong, Peony
    Tam, Terence Chi-Chun
    Lam, David Chi-Leung
    Ip, Mary Sau-Man
    Lee, Yun-Chor Gary
    Lui, Macy Mei-Sze
    RESPIROLOGY, 2020, 25 (11) : 1167 - 1173
  • [34] Effect of malignant-associated pleural effusion on endothelial viability, motility and angiogenesis in lung cancer
    Changchien, Chih-Ying
    Chen, Ying
    Chang, Hsin-Han
    Chang, Shan-Yueh
    Tsai, Wen-Chiuan
    Tsai, Hao-Chung
    Wang, Chieh-Yung
    Lee, Herng-Sheng
    Tsai, Chen-Liang
    CANCER SCIENCE, 2020, 111 (10) : 3747 - 3758
  • [35] Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion
    Qinpei Cheng
    Xueying Zuo
    Zimu Wang
    Wanjun Lu
    Yuxin Jiang
    Jiaxin Liu
    Xinying Li
    Qiuli Xu
    Suhua Zhu
    Xin Liu
    Yong Song
    Ping Zhan
    Tangfeng Lv
    Respiratory Research, 26 (1)
  • [36] TRANSKETOLASE INVOLVED CANCER CELL PROLIFERATION AND VEGF SECRETION IN LUNG ADENOCARCINOMA ASSOCIATED MALIGNANT PLEURAL EFFUSION
    Lin, Chien-Chung
    Su, Wu-Chou
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S957 - S958
  • [37] Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: A multi-institutional phase II trial
    Maruyama, Riichiroh
    Yokoyama, Hideki
    Seto, Takashi
    Nagashima, Seiji
    Kashiwabara, Kosuke
    Araki, Jun
    Semba, Hiroshi
    Ichinose, Yukito
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (01) : 65 - 68
  • [38] Cancer-associated fibroblasts promote the malignant development of lung cancer through the FOXO1 protein/LIF signaling
    Shen, Jiannan
    Wu, Wei
    Zhang, Xing
    Xie, Xiaodong
    Shen, Wenrong
    Wang, Qianghu
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 276
  • [39] THE PIGTAIL CATHETER VS. CHEST TUBE IN THE MANAGEMENT OF MALIGNANT PLEURAL EFFUSION OF ADVANCED LUNG CANCER.
    Choi, Chang Min
    Kim, Go Woon
    Kim, Sun Young
    Lee, Seung Yeon
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S503 - S504
  • [40] The management of elderly patients with lung cancer: a single center retrospective study
    Wang, Ping
    Li, Chunyan
    An, Yang
    Wang, Xiaoqian
    Liang, Zhixin
    Chen, Liang'an
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (01) : 229 - 237